Skip to Content

Join the 'Leukemia' group to help and get support from people like you.

Leukemia News

Related terms: Cancer, Leukemia

Health Tip: Talking With Your Child's Cancer-Care Team

Posted 4 days ago by Drugs.com

-- If your child has cancer and is being treated by a team of specialists, frequent and open communication is essential. The American Cancer Society suggests how to talk with team members: Actively take part in your child's care. Communication should be clear, direct and honest. Treat team members with respect. Provide thorough and accurate information about your child's health history. Address any confusion, frustration or disagreement directly with the team members involved. Develop positive and strong relationships with team members. Maintain reasonable expectations about how much time team members can spend with the patient and your family. Keep a running list of questions for team members. Ask for explanations of medical or technical terms you don't understand. Take notes during important discussions. Keep a log of all hospitalizations, tests and treatments. Read more

Related support groups: Cancer, Leukemia

Health Tip: Accept Help if Your Child Has Cancer

Posted 11 days ago by Drugs.com

-- Caring for a child with cancer can be emotionally and physically overwhelming. The Children's Oncology Group says the best thing such a parent can do is to accept help from friends and family. The group mentions these benefits of doing so: You will have more energy to take care of your child, spend time with your other children and connect with your partner. While there are some things that only you or your spouse can do for your child, there are plenty of things such as grocery shopping, cleaning, cooking and carpooling that others can help you with. Having support can help you feel better when coming to terms with a cancer diagnosis. Read more

Related support groups: Anxiety and Stress, Cancer, Leukemia

Are You Sure That's What the Doctor Said About Your Leukemia?

Posted 18 days ago by Drugs.com

THURSDAY, Nov. 2, 2017 – The stress of a frightening leukemia diagnosis may impede clear doctor-patient communication, a new study suggests. Patients undergoing chemotherapy treatment for acute myeloid leukemia (AML) tend to view their illness and prognosis through a different lens from their doctors, researchers say. Investigators found that patients are inclined to overestimate their risk of dying due to treatment and, at the same time, overestimate their chances for a full cure. "Patients with AML face very challenging treatment decisions that are often placed upon them within days after being diagnosed," said senior study author Dr. Areej El- Jawahri. "Because they face a grave decision, they need to understand what the risks of treatment are versus the possibility of a cure," said El-Jawahri, an assistant professor of medicine at Massachusetts General Hospital in Boston. Adult AML ... Read more

Related support groups: Leukemia, Acute Myeloid Leukemia

FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia

Posted 1 Sep 2017 by Drugs.com

September 1, 2017 – The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). Mylotarg originally received accelerated approval in May 2000 as a stand-alone treatment for older patients with CD33-positive AML who had experienced a relapse. Mylotarg was voluntarily withdrawn from the market after subsequent confirmatory trials failed to verify clinical benefit and demonstrated safety concerns, including a high number of early deaths. Today’s approval includes a lower recommended dose, a different schedule in combination with c ... Read more

Related support groups: Cancer, Leukemia, Acute Myeloid Leukemia, Mylotarg, Gemtuzumab

FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg

Posted 1 Sep 2017 by Drugs.com

FRIDAY, Sept. 1, 2017 – The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia – CD33-positive AML. An earlier version of the drug had been withdrawn from the market when health risks started to emerge. Known generically as gemtuzumab ozogamicin, the drug received the go-ahead to treat adults newly diagnosed with CD33-positive AML. It also can treat children aged 2 years and older with the disease if they've relapsed or have not responded to initial treatment, the FDA said in a news release. AML is a rapidly progressing cancer. It forms in the bone marrow and elevates the number of white blood cells in the bloodstream. More than 21,000 people will be diagnosed with AML this year in the United States, and about 10,600 will die of it, according to the U.S. National Cancer Institute. This isn't ... Read more

Related support groups: Cancer, Leukemia, Acute Myeloid Leukemia, Mylotarg, Acute Promyelocytic Leukemia

FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

Posted 31 Aug 2017 by Drugs.com

South San Francisco, CA – August 30, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and older. CRS, which is caused by an overactive immune response, has been identified as a potentially severe and life-threatening side effect of CAR T cell therapy for certain cancers.1 “Until today, there has never been an FDA-approved treatment to manage severe cytokine release syndrome associated with CAR T cell therapy, which is marked by a rapid onset and can cause life-threatening complications,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Today's ... Read more

Related support groups: Cancer, Leukemia, Actemra, Acute Lymphoblastic Leukemia, Tocilizumab, Cytokine Release Syndrome

First Gene Therapy Kymriah (tisagenlecleucel) Approved in U.S.

Posted 30 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 30, 2017 – The U.S. Food and Drug Administration on Wednesday approved the first gene therapy in the United States, to treat children and young adults with a particularly tough type of leukemia. Kymriah (tisagenlecleucel) is for B-cell acute lymphoblastic leukemia (ALL), the agency said in a news release. "We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," said FDA Commissioner Dr. Scott Gottlieb. "New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses." Each dose of Kymriah is created using the person's own immune system T-cells. These cells are lab-modified and then reinfused into the patient to target and kill leukemia cells, the FDA explained. ALL is an ... Read more

Related support groups: Cancer, Leukemia, Acute Lymphoblastic Leukemia, Kymriah, Tisagenlecleucel

FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia

Posted 30 Aug 2017 by Drugs.com

August 30, 2017 – The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, M.D. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be li ... Read more

Related support groups: Cancer, Leukemia, Acute Lymphoblastic Leukemia, Kymriah, Tisagenlecleucel

FDA Approves First Gene Therapy, Kymriah, for Use in U.S.

Posted 30 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 30, 2017 – The U.S. Food and Drug Administration broke new ground in cancer care Wednesday by approving the first gene therapy for patients in the United States. Kymriah (tisagenlecleucel) genetically tweaks a patient's own immune system cells into what scientists call "a living drug" to battle a form of acute lymphoblastic leukemia (ALL). The immunotherapy now can be used in children and young adults with B-cell ALL that will not respond to other therapies, the FDA announced. "We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," FDA Commissioner Dr. Scott Gottlieb said in an FDA news release. ALL is a cancer of the bone marrow and blood in which the body makes abnormal lymphocytes, a type of white blood cell. Dr. Kenneth Anderson is president of the American Society of Hematology, which ... Read more

Related support groups: Leukemia, Acute Lymphocytic Leukemia

FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia

Posted 21 Aug 2017 by Drugs.com

August 17, 2017 – The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). “For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “These patients have few treatments available and today’s approval provides a new, targeted treatment option.” B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. The National Cancer Institute estimates that approximate ... Read more

Related support groups: Leukemia, Acute Lymphoblastic Leukemia, Besponsa, Inotuzumab Ozogamicin

FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia

Posted 3 Aug 2017 by Drugs.com

August 3, 2017 – The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine. “This is the first approved treatment specifically for patients with certain types of high-risk AML,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer than if they were to receive the two therapies separately.” AML is a rapidly progressing cancer that forms in the bone marrow and results in an i ... Read more

Related support groups: Cancer, Leukemia, Acute Myeloid Leukemia, Blood Cancer, Cytarabine, Daunorubicin, Vyxeos, Cytarabine/daunorubicin, Cytarabine Liposomal, Daunorubicin Liposomal

New Combination Treatment, Vyxeos, Approved for Acute Myeloid Leukemia

Posted 3 Aug 2017 by Drugs.com

THURSDAY, Aug. 3, 2017 – The combination chemotherapy drug Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration as the first treatment for certain high-risk types of acute myeloid leukemia (AML). AML is an aggressive blood cancer that forms in the bone marrow. "Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer than if they were to receive the two therapies separately," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence. In a news release Thursday, the agency said more than 21,000 people will be diagnosed this year with AML, and more than 10,000 will die from it, according to projections from the U.S. National Cancer Institute. The new therapy is sanctioned for high-risk forms of newly-diagnosed therapy-related AML (t-AML) or AML with ... Read more

Related support groups: Leukemia, Acute Myeloid Leukemia, Cytarabine, Daunorubicin, Cytosar, Cytosar-U, Tarabine PFS, Cerubidine

FDA Approves Idhifa (enasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation

Posted 1 Aug 2017 by Drugs.com

August 1, 2017 – The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. “Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The use of Idhifa was associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.” AML is a rapidly progressing c ... Read more

Related support groups: Cancer, Leukemia, Acute Myeloid Leukemia, Blood Cancer, Idhifa, Enasidenib

FDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.

Posted 13 Jul 2017 by Drugs.com

WEDNESDAY, July 12, 2017 – A U.S. Food and Drug Administration advisory panel on Wednesday gave unanimous approval to what could soon be the first gene therapy to be marketed in the United States. The treatment, called CTL019, genetically tweaks a patient's own immune system cells into what scientists call "a living drug" to battle a form of acute lymphoblastic leukemia (ALL), The New York Times reported. The FDA's probable acceptance of such a strong recommendation may open a new era of gene-based medicines, which have for so long held only promise against a range of diseases. "When fully commercialized, this [CTL019] therapy will no doubt save the lives of many children and young adults who have had no other effective therapy for relapsed and refractory B-cell acute lymphoblastic leukemia [ALL]," said Dr. John Maris, a pediatric oncologist at The Children's Hospital of Philadelphia. ... Read more

Related support groups: Cancer, Leukemia, Acute Lymphoblastic Leukemia, Diagnosis and Investigation

FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

Posted 12 Jul 2017 by Drugs.com

THOUSAND OAKS, Calif., July 11, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. The approval converts Blincyto's accelerated approval to a full approval. The sBLA approval also included data from the Phase 2 ALCANTARA study supporting the treatment of patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The approval expands the indication of Blincyto for the treatment of relapsed or refractory B-cell precursor ALL in adults and children. "For researchers and physicians, overall survival is the primary goal of treatment and the gold standard of outcomes, demonstrating a clear value to patients," ... Read more

Related support groups: Leukemia, Acute Lymphoblastic Leukemia, Blincyto, Blinatumomab

Page 1 2 3 4 5 6 7 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Nonlymphocytic Leukemia, Hairy Cell Leukemia, Acute Myeloblastic Leukemia, Chronic Eosinophilic Leukemia, Meningeal Leukemia, Blood Disorders

Related Drug Support Groups

prednisone, dexamethasone, triamcinolone, Sprycel, Decadron, cytarabine, Deltasone, dasatinib, Fludara, view more... Kenalog-40, Adrenocot, Adrenocot LA, Sterapred DS, Liquid Pred, Dexone, Cytosar, Cytosar-U, Sterapred, Solurex LA, Orasone, Decaject LA, Decaject, Dalalone LA, Dalalone DP, Dalalone, Baycadron, Oforta, fludarabine, Dexamethasone Intensol, Idamycin, Clinacort, Prednicot, idarubicin, Prednicen-M, Idamycin PFS, Dexacen-4, Decadron-LA, Solurex, Tarabine PFS, De-Sone LA, Dexacort-LA, Dexasone, Dexasone LA, Dexone LA, Meticorten, Primethasone, Dexacorten, Medidex, Medidex LA, Dexpak Taperpak, Hexadrol, Zema Pak